PSS38 3-D Study - Description of the Care of the Dental Pain

Abstract

Highlight the action of two analgesics combining paracetamol and codeine (Klipal 600® and EfferalganDafalgan Codeine®), with a minimum of 50 mg of codeine at a time. Multicentre, longitudinal, prospective, observational study, performed in metropolitan France from data collected by the dental surgeons that have accepted to participate in it. A total of 105 patients were included. Klipal 600® was prescribed for 76 of them versus 24 for the other group. 56.2% of the patients are women. The average age is 45.57 + 14.64. The measurement of the average pain intensity, evaluated each day over a 6 day period by a VAS, shows an insignificant difference at the inclusion between the 2 groups (p = 0.23). But, contrary to the Efferalgan/Dafalgan codeine® group, the score differential for the pain intensity is statistically significant between Day 1 and Day 2 with the Klipal 600® group and the improvement is significant up to the fourth day. The pain qualification was evaluated by the Saint Antoine pain questionnaire (abbreviated format) bearing on 16 sensory and emotional qualifiers specifying the description of the pain experienced. The difference is not significant between the 2 groups at the inclusion (p = 0.09), then it is observed that the pain qualification score is reduced beginning on the second day for the 2 groups. For the 2 groups, it is observed that the average number of tablets is in the order of 2.3 during the first 48 hours with a similar progressive decrease up to the sixth day. The prescription of one tablet at a time for the Klipal® is an advantage for the follow up of the treatment and its effectiveness. In reality, this study demonstrates a quicker improvement in pain in the Klipal® group, also associated with reduced consumption of the treatment and a better effectiveness.